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Sequencing of tumors is now routine and guides personalized cancer ther-
apy. Mutant allele fractions (MAFs, or the ‘mutation dose’) of a driver
gene may reveal the genomic structure of tumors and influence response to
targeted therapies. We performed a comprehensive analysis of MAFs of
driver alterations in unpaired primary and metastatic colorectal cancer
(CRC) at our institution from 2010 to 2015 and studied their potential clin-
ical relevance. Of 763 CRC samples, 622 had detailed annotation on over-
all survival in the metastatic setting (OSmet) and 89 received targeted
agents matched to KRAS (MEK inhibitors), BRAF (BRAF inhibitors), or
PIK3CA mutations (PI3K pathway inhibitors). MAFs of each variant were
normalized for tumor purity in the sample (adjMAFs). We found lower
adjMAFs for BRAFV600E and PIK3CA than for KRAS, NRAS, and BRAF
non-V600 variants. TP53 and BRAFV600E adjMAFs were higher in metas-
tases as compared to primary tumors, and high KRAS adjMAFs were
found in CRC metastases of patients with KRAS wild-type primary tumors
previously exposed to EGFR antibodies. Patients with RAS- or
BRAFV600E-mutated tumors, irrespective of adjMAFs, had worse OSmet.
There was no significant association between adjMAFs and time to pro-
gression on targeted therapies matched to KRAS, BRAF, or PIK3CA
mutations, potentially related to the limited antitumor activity of the
employed drugs (overall response rate of 4.5%). In conclusion, the lower
BRAFV600E and PIK3CA adjMAFs in subsets of primary CRC tumors
indicate subclonality of these driver genes. Differences in adjMAFs
between metastases and primary tumors suggest that approved therapies
may result in selection of BRAFV600E- and KRAS-resistant clones and an
increase in genomic heterogeneity with acquired TP53 alterations. Despite
significant differences in prognosis according to mutations in driver onco-
genes, adjMAFs levels did not impact on survival and did not help predict
benefit with matched targeted agents in the metastatic setting.
Abbreviations
CRC, colorectal cancer; MAFs, mutant allele fractions.
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1. Introduction
Tumor next-generation sequencing (NGS) is routine
part of prescreening programs to guide precision can-
cer therapy. NGS allows the identification of muta-
tions in driver genes in a very sensitive and
quantitative manner. The mutant allele fractions
(MAFs), also called ‘mutation dose’, represent the
number of mutant reads divided by the total number
of reads – coverage – at a specific genomic position. In
some scenarios, the MAFs of driver genes may have
important clinical implications. Examples include the
upfront resistance to anti-EGFR therapies in meta-
static colorectal cancer (CRC) with KRAS MAFs as
low as 1% (Azuara et al., 2016; Laurent-Puig et al.,
2015), or the positive association between higher
EGFRL858R MAFs in lung cancer specimens and
longer duration of treatment benefit with gefitinib and
erlotinib in the metastatic setting (Ono et al., 2014;
Zhou et al., 2011). More recently, investigators have
been tracking MAFs of driver genes to infer muta-
tional timeline and depict dynamic clonal evolution in
individual tumors exposed to targeted agents
(McGranahan et al., 2015; Murtaza et al., 2015; Russo
et al., 2016).
In tissue samples, the MAFs are largely influenced
by tumor purity (fraction of neoplastic cells in the
sample) and ploidy (either copy number gains or losses
of wild-type/mutant alleles). It is possible to partially
adjust the MAF of a mutation by normalizing it to
the neoplastic cell content of the sample, which can be
named an ‘adjusted MAF’ (adjMAF). Interestingly,
when examining NGS results, MAFs do not clearly
correlate with tumor purity, and in samples with more
than one mutation, adjMAFs are often different
among the affected genes (Normanno et al., 2015).
These findings suggest either coexisting gene mutations
and copy number alterations or intratumor genomic
heterogeneity, with clonal (truncal) and subclonal dri-
ver gene mutations in the same tumor sample.
In many cancer types, including CRC, a comprehen-
sive analysis of driver genes adjMAFs remains to be
performed, with particular attention to differences
between primary and metastatic lesions, or after expo-
sure to standard therapies. In addition, the potential
prognostic effect of a driver gene ‘mutation dose’ in
solid tumors has not been investigated in detail. In this
manuscript, we present an in-depth analysis of
adjMAFs of driver genes in CRC and estimate their
relative clonal and subclonal distribution. We also
investigate their potential clinical impact in a large
patient cohort with outcome annotation, focusing on
survival in the metastatic setting and on the magnitude
of response to matched targeted therapies, namely
anti-MEK, anti-BRAF, and anti-PI3K agents accord-
ing to KRAS, BRAFV600E, and PIK3CA adjMAFs,
respectively.
2. Materials and methods
2.1. Mutation analysis and populations of
interest
From 2010 to 2015, 763 consecutive patients with
metastatic CRC were eligible for targeted sequencing
at our institution (Vall d’Hebron Institute of Oncol-
ogy, VHIO) as part of a molecular prescreening pro-
gram (MPP) for early drug development. From
January 2010 to May 2014, mutation detection and
quantification was performed using a multiplex mass
spectrometry-based technology (massARRAY Seque-
nom platform, with a 24 oncogene panel of hotspot
mutations, including most frequent variants in KRAS,
NRAS, BRAF, and PIK3CA). Thereafter, we moved
to an amplicon-based NGS technology (MiSeq Illu-
mina platform, with a 61 oncogene plus tumor sup-
pressor panel, covering most frequently mutated exons
of KRAS, NRAS, BRAF, PIK3CA, APC, and TP53).
Technical details of mutation analysis are described in
Doc S1. Both tests were performed in-house in our
Cancer Genomics Lab under ISO accreditation (UNE-
EN ISO 15189:2013) including mutation detection and
quantification. Average sequencing depth was 10009
allowing precise estimates for low MAFs (mutations
were called at a minimum MAF of 3%). We used
archived formalin-fixed paraffin-embedded tissues for
sequencing after pathological assessment of neoplastic
cell content in the sample by the Molecular Oncology
Lab. Tumor purity was defined as the amount of sam-
ple occupied by cancer cells and not by surrounding
stromal and immune/inflammatory cells, that is, per-
centage of transformed (neoplastic) cells. In order to
mitigate variability, the quantification of neoplastic
cells was performed by an experienced pathologist
(P.N.) always in the same section used for sequencing,
as recently recommended by other groups (Lhermitte
et al., 2017). A minimum of 20% tumor purity was
required for sample processing (resolution at 5%
level). Heterogeneous tissue samples were macrodis-
sected for tumor purity assessment and molecular
analysis. The calculated adjMAFs (MAF/tumor pur-
ity) of driver genes of interest were used to infer clon-
ality of the events. In summary, for oncogenes, the
expected adjMAF is close to 0.5 if the event is clonal
and < 0.5 if subclonal. For tumor suppressors, as dele-
tion of the wild-type allele (loss of heterozygosity) is a
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common genomic event, the expected adjMAFs is
> 0.5 if the event is clonal.
Of 763 patients with targeted mutation profiling
(molecular population), 622 received oncologic treat-
ment at VHIO and had complete survival annotation
(molecular + clinical population). Data curators from
the Oncology Data Science (ODysSey) group prospec-
tively extracted this information from medical records
in structured clinical–molecular databases. The remain-
ing patients were external referrals to MPP and did
not have clinical interventions at our institution. From
622 molecularly and clinically eligible patients, 34 with
KRAS-mutated tumors were enrolled in clinical trials
with MEK inhibitors, 20 with BRAFV600E-mutated
tumors received anti-BRAF therapy, and 35 with
PIK3CA-mutated tumors were treated with an anti-
PI3K agent. Treatment on phase 1 studies continued
until disease progression or unacceptable toxicity and
was carried out according to the specific requirements
of each protocol. Tumor responses were classified as
complete, partial, stable disease, or progressive disease
as per Response Evaluation Criteria in Solid Tumors
(RECIST) v 1.1. Time to progression (TTP) was
defined as the time interval from the start of a therapy
to its discontinuation for disease progression or death,
whichever occurred first (patients with permanent
treatment discontinuation for toxicity without evidence
of progressive disease were censored at the time of last
dose). Overall survival in the metastatic setting
(OSmet) was defined as time from first diagnosis of
metastasis until death or last follow-up.
2.2. Statistical and ethical considerations
Nonparametric tests (Mann–Whitney U and Kruskal–
Wallis) were used to cross-compare adjMAFs of differ-
ent genes and correlate with variables of interest, such
as tissue source (CRC primary vs. metastatic site). Sur-
vival analyses (TTP and OSmet) were conducted using
the Kaplan–Meier method and compared with the log-
rank test. We constructed univariate and multivariable
Cox proportional hazard models for OSmet. The asso-
ciation between TTP and adjMAFs was measured
using Pearson’s correlation. All tests were two-sided,
and a P value < 0.05 was considered statistically signif-
icant. Statistical analyses were conducted using R ver-
sion 3.2.3 (survival and phenoTest packages). All
patients that participated in our institutional MPP
signed informed consent form giving investigators
access to molecular and clinical data for research pur-
poses. All clinical trials were conducted in accordance
with the guidelines of the VHIO Institutional Review
Board.
3. Results
3.1. Biological insights from analysis of driver
genes adjMAFs in CRC
As shown in Table 1, sequencing was mostly per-
formed on samples derived from CRC primary tissue.
Patients whose metastatic sites were used for profiling
had prior exposure to systemic therapies at the time of
sample acquisition. This population had sequencing
performed exclusively in the metastatic site – unpaired
samples. Median tumor purity was 50% (IQR 35–
70%), with no significant differences when comparing
samples that harbored mutations in driver genes and
those wild-type for the respective genes (P > 0.05) or
according to the tissue source used for profiling
(P = 0.16).
The prevalence of oncogene mutations in our cohort
is depicted in Fig. 1A. The lower prevalence of APC
mutations (51%) as compared to published literature
(around 70%; The Cancer Genome Atlas, 2012) is
related to a limited APC exon coverage of our NGS
panel. Inspection of adjMAFs distribution (Fig. 1B,C)
revealed major differences across driver genes. Relative
to a simulated normal distribution of adjMAF accord-
ing to the ‘one-hit hypothesis’ for oncogenes (median
0.5, IQR 0.25–0.75), we observed significantly lower
adjMAFs for BRAF (median 0.31, IQR 0.23–0.50;
P < 0.001) and PIK3CA (median 0.38, IQR 0.25–0.56;
P < 0.001), suggesting a potential subclonality of these
genomic alterations. TP53 adjMAFs (median 0.66,
IQR 0.40–0.85) were significantly higher than simu-
lated cohort (P < 0.001), indicating a clonal event plus
deletion of wild-type allele in most samples. There
were no significant differences between adjMAFs of
oncogenes KRAS (median 0.56, IQR 0.42–0.77;
P = 0.66) and NRAS (median 0.49, IQR 0.33–0.66;
P = 0.44) as compared with normal distribution, rein-
forcing clonality of these events. The same was true
for APC adjMAFs (median 0.50, IQR 0.32–0.83;
P = 0.87). Of note, we compared the distribution of
oncogene adjMAF according to platform (Sequenom
or MiSeq Illumina) and found no statistically signifi-
cant differences (P > 0.05 for KRAS, NRAS, BRAF,
and PIK3CA).
Next, we investigated in more detail the potential
subclonality of BRAF and PIK3CA mutations in
CRC. Taking advantage of our institutional molecular
database, we compared adjMAFs in CRC with those
of other malignancies having frequent mutations in
these genes. We selected samples from other tumors
profiled during the same time period and using similar
platforms. As shown in Fig. 1D, BRAFV600E adjMAFs
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were significantly higher in skin melanomas (median
0.42, IQR 0.25–0.68; n = 25; P = 0.03) than in CRC.
With regard to PIK3CA mutations, depicted in
Fig. 1E, an intermediate adjMAFs level was seen in
CRC as compared to breast cancer (median 0.46, IQR
0.29–0.65; n = 64; P = 0.002) and gynecological malig-
nancies (median 0.27, IQR 0.19–0.40; n = 56;
P = 0.05). This suggests that PIK3CA mutations may
be either clonal or subclonal events in CRC. Indeed,
when comparing adjMAFs of PIK3CA and KRAS in
CRC samples with co-occurring mutations (Fig. S1A),
we confirmed that potential subclonality of PIK3CA
mutations is restricted to a subset of CRC tumors (32
of 86 samples [37.2%] with KRAS/PIK3CA adjMAFs
ratio > 1.5).
We then explored differences in adjMAFs of driver
oncogenes in CRC according to codon or domain
affected and tissue source. As illustrated in Fig. S1B,
only BRAF adjMAFs vary according to codon
affected, being significantly higher in non-V600 muta-
tions (median 0.48, IQR 0.39–0.85; n = 9) as compared
to V600 variants (median 0.28, IQR 0.22–0.44; n = 56;
P = 0.003; Fig. 1F). A stratified analysis based on tis-
sue source (Fig. S1C) showed TP53 adjMAFs
Table 1. Population characteristics.
Molecular population (n = 763)
Mutation analysis Sequenom 460 (60.3%)
MiSeq 303 (39.7%)
Tissue source CRC primary 586 (79.7%)
Metastasis 149 (20.3%)
Missing 28
Driver mutation KRAS 365 (47.8%)
NRAS 29 (3.8%)
BRAF 65 (8.5%)
PIK3CA 128 (16.7%)
APC (MiSeq only) 154 (50.8%)
TP53 (MiSeq only) 191 (63.0%)
Molecular–clinical population (n = 622)
Age at diagnosis Median (range) 58 years (22–85)
Gender Male 386 (62%)
Female 236 (38%)
Stage at diagnosis Early 252 (41%)
Metastatic 370 (59%)
CRC primary site Right 178 (30%)
Left 260 (45%)
Rectum 145 (25%)
Number of metastatic sites at diagnosis of metastasis One 419 (67%)
Two 163 (26%)
Three or more 40 (7%)
Metastatic sites Liver 407 (65%)
Lung 186 (30%)
Node 131 (21%)
Peritoneal 94 (15%)
Other 57 (9%)
Surgical treatment for metastasis Any 285 (46%)
Liver 195 (31%)
Lung 52 (8%)
Other sites 57 (9%)
Pharmacological treatment Oxaliplatin based 599 (97%)
Irinotecan based 549 (89%)
Antiangiogenic therapy 342 (55%)
Anti-EGFR therapy 285 (46%)
Anti-MEK therapya 52 (8%)
Anti-BRAF therapyb 20 (3%)
Anti-PI3K therapyc 70 (11%)
Any other experimental therapy 169 (28%)
aRAS mutated or wild-type, single agent or combo; bBRAF mutated, single agent, or combo; cPIK3CA mutated or wild-type, single agent, or
combo.
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significantly higher in metastases (median 0.76, IQR
0.51–1.00; n = 63) than CRC primaries (median 0.60,
IQR 0.38–0.83; n = 126; P = 0.005; Fig. 1G), suggest-
ing that TP53 copy number alterations are more fre-
quent in CRC metastases. A trend for higher
BRAFV600E adjMAFs in metastatic sites (median 0.48,
IQR 0.32–0.62; n = 6) than CRC primaries (median
0.27, IQR 0.21–0.40; n = 48; P = 0.11; Fig. 1H) was
also identified. Four of six BRAFV600E metastatic
lesions had prior exposure to anti-EGFR therapy.
Finally, we identified a population with KRAS-
mutated metastatic tumors that received treatment
with EGFR antibodies prior to biopsy of metastatic
site, based on a diagnosis of KRAS wild-type in CRC
primary performed outside our institution. As shown
in Fig. 1I, KRAS adjMAFs of these samples (median
0.43, IQR 0.43–0.50; n = 5) were not significantly dif-
ferent from those without prior anti-EGFR therapy
exposure (median 0.6, IQR 0.43–1.1; n = 41;
P = 0.13).
3.2. Clinical impact of driver genes adjMAFs in
CRC
First, we investigated whether the presence of driver
oncogene mutations had an impact on prognosis of
metastatic CRC patients. As shown in Table 1, this
represents an unselected population treated at our
institution in the last 6 years, including patients eligi-
ble to surgical resection of metastasis during the
course of their disease (46%). Most patients had liver
metastasis only at diagnosis and were exposed to
oxaliplatin- and irinotecan-based chemotherapy plus
antiangiogenic agents or anti-EGFR therapy (if RAS
wild-type). In addition, close to 40% of our patients
received experimental agents in early clinical trials in
the third- or fourth-line settings. Median follow-up of
patients alive was 38 months (IQR 22–64 months).
When aggregating patients in subgroups based on
oncogene mutations, as illustrated in Kaplan–Meier
curves of Fig. 2A, we observed major differences in
median OSmet. In univariate Cox models, detailed in
Table 2, we found that patients whose tumors har-
bored either RAS or BRAF mutations had significantly
worse OSmet when compared to quadruple wild-type
(KRAS, NRAS, BRAF, and PIK3CA) tumors.
PIK3CA mutations, when having either a more clonal
or subclonal pattern of adjMAFs coexisting with RAS
mutations, did not negatively impact on OSmet, as
illustrated in Fig. S2A. Survival was not significantly
different according to KRAS or NRAS codon affected,
and only BRAFV600E-mutated tumors had a statistical
association with worse OSmet as compared with
tumors harboring KRAS G12 events, as shown in
Fig. S2B and detailed in Table 2. We also found no
effect of KRAS mutation clonality on survival when
considering KRAS adjMAFs as a continuous variable
(P = 0.37), as illustrated in Fig. 2B. Similarly, in the
BRAFV600E-mutated population, BRAF adjMAFs did
not impact on prognosis (P = 0.34; results not shown).
Next, we constructed a multivariable Cox model with
all clinicopathological and molecular covariates that
demonstrated statistically significant (P < 0.05) associ-
ation with OSmet in univariate models. The results of
Fig. 1. Biological insights into mutant allele fractions adjusted for tumor purity (adjMAFs) in CRC. Proportion of CRC samples with
mutations in driver genes (A) and distribution of adjMAFs for the respective genes (B, C). BRAFV600E adjMAFs are higher in melanomas as
compared to CRC (D), and PIK3CA adjMAFs are higher in breast cancer and lower in gynecological malignancies as compared to CRC (E).
BRAF adjMAFs are different according to codon affected (higher in non-V600 mutations as compared to V600; F) and tissue source (trend
for higher counts in metastases as compared to CRC primaries; G). TP53 adjMAFs are also higher in metastases as compared to CRC
primaries (H). KRAS adjMAFs in metastases of patients with prior exposure to EGFR antibodies (originally KRAS wild-type in the primary
tissue) are not significantly different from those without prior targeted treatment (with constitutive KRAS mutations in primary tissue) (I).
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our model that included gender, location of CRC pri-
mary, the number of metastatic sites, surgical resection
of metastasis, RAS mutations, and BRAFV600E muta-
tions are detailed in Table 2. Surgical treatment of
metastasis was the strongest determinant of survival in
our population, followed by driver oncogene muta-
tions. We also observed a statistically significant effect
of CRC primary location on OSmet, with higher risk
of death for patients with right-sided tumors, irrespec-
tive of mutations in RAS and BRAFV600E.
As prognosis was not affected by clonality of driver
oncogenes, we investigated their potential impact on
duration of treatment benefit with matched targeted
agents. Detailed description of the population and reg-
imens under investigation can be seen in Table 3.
Complete or partial responses were only observed in
five patients (20%) with BRAFV600E-mutated tumors
treated with combination regimens. Median TTP was
1.8 months (CI 95% 1.4–2.4) with MEK inhibitors
(given as doublets with another targeted agent) in
patients with KRAS-mutated tumors, 3.15 months (CI
95% 1.9–6.7) with BRAF inhibitors (given as single
agents, doublets, or triplets) in patients with
BRAFV600E-mutated tumors and 2.10 months (CI 95%
1.9–2.6) with PI3K inhibitors (given as single agents)
in patients with PIK3CA-mutated tumors. As illus-
trated in Fig. 2C–E, we found no association between
adjMAFs and TTP on matched therapy: Pearson’s
correlations of 0.12 (CI 95% 0.44 to 0.22;
P = 0.48), 0.02 (CI 95% 0.46 to 0.43; P = 0.94), and
0.05 (CI 95% 0.29 to 0.37; P = 0.79) for MEK,
BRAF, and PI3K inhibitors, respectively.
4. Discussion
NGS of patient tumors has been rapidly incorporated
into both prescreening programs and clinical trials
over the last years, with the goal of identifying gene
alterations that can guide individualized decisions.
MAFs of driver genes reflect the genomic complexity
of tumors, which may influence prognosis and
response to targeted therapies. However, MAFs are
Fig. 2. Clinical insights into mutant allele fractions adjusted for tumor purity (adjMAFs) in CRC. Overall survival in the metastatic setting is
affected by mutation subgroup (A). The clonality of KRAS mutations (as continuous adjMAFs values) does not impact on survival models (B).
There is no correlation between KRAS, BRAFV600E, and PIK3CA adjMAFs and TTP on matched targeted therapies, as shown in C–E.
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frequently underreported or overlooked, which
prompted us to investigate whether they have an
impact in CRC evolution in the metastatic setting. Our
results indicate clonality of RAS mutations and poten-
tial subclonality of BRAFV600E mutations and a subset
of PIK3CA mutations in primary CRC tumors. Nor-
manno et al. (2015) also found that in most CRC, the
majority of neoplastic cells carry mutant KRAS or
NRAS, while in BRAF- and PIK3CA-mutant cases,
only a fraction of neoplastic cells harbor the mutant
allele. Alternatively, repetitive copy number alterations
co-occurring with mutations in driver genes could
reduce BRAF and PIK3CA adjMAFs counts. How-
ever, the published literature does not support this
hypothesis: BRAF and PIK3CA mutations rarely co-
occur with copy number gains in wild-type alleles (The
Cancer Genome Atlas, 2012; Zack et al., 2013). Arm-
level 7q gains (BRAF locus) have been described in up
to 40% of CRC samples, mainly chromosomally insta-
ble tumors lacking BRAF mutations (The Cancer Gen-
ome Atlas, 2012). In fact, from 20 BRAFV600E-mutated
samples in TCGA cohort, only three cases (15%) had
coexisting low-level BRAF copy number gains that
could possibly explain a lower adjMAF count (The
Cancer Genome Atlas, 2012). Similarly, repetitive
chromosome 3q gains (PIK3CA locus) have not been
reported in non-Asian CRC samples (He et al., 2003).
Indeed, from 33 PIK3CA-mutated samples in TCGA
cohort, only two cases (6%) had coexisting low-level
PIK3CA copy number gains (The Cancer Genome
Atlas, 2012). Therefore, we believe that BRAFV600E
and PIK3CA mutations are real subclonal events in
subsets of primary CRC tumors.
Other studies have also described clonal–subclonal
frequencies of driver alterations in cancer. In a com-
prehensive analysis of TCGA data in nine solid
tumors, McGranahan et al. (2015) found a clear ten-
dency for mutations in driver genes to be clonal com-
pared to mutations in noncancer genes. Interestingly,
genes involved in the PI3K-AKT-mTOR pathway,
such as PIK3CA, had a higher proportion of subclonal
events compared to genes associated with RAS-MAPK
pathway, including KRAS, NRAS, and BRAF. There
were clear differences in clonality of PIK3CA and
Table 2. Univariate and multivariable Cox models.
Univariate models
Subgroup No. at risk No. events
Median OSmet
(months) [CI 95%]
Univariate HR
[CI 95%] P value (log-rank)
RAS/BRAFwt PIK3CAwt 227 143 48.7 [42.4–55.7] Control
RAS/BRAFwt PIK3CAmut 19 12 59.2 [43.9–NR] 0.84 [0.47–1.52] 0.57
RASmut PIK3CAwt 250 157 37.0 [32.8–42.2] 1.43 [1.14–1.79] 0.002
RASmut PIK3CAmut 78 53 36.5 [28.8–46.8] 1.60 [1.17–2.20] 0.004
BRAFmut 44 31 27.2 [19.9–46.2] 2.31 [1.57–3.43] < 0.001
RASmut PIK3CAwt 250 157 37.0 [32.8–42.2] Control
RASmut PIK3CAmut clonal 44 32 36.8 [27.8–51.4] 1.20 [0.82–1.76] 0.35
RASmut PIK3CAmut subclonal 28 19 32.8 [23.7–NR] 1.15 [0.71–1.85] 0.57
KRASmut codon 12 228 156 39.3 [35.1–42.9] Control
KRASmut codon 13 46 29 29.5 [22.6–42.8] 1.45 [0.97–2.18] 0.06
KRASmut codon other 29 15 36.2 [29.7–NR] 0.79 [0.46–1.34] 0.38
NRASmut any codon 25 12 51.4 [35.3–NR] 0.68 [0.38–1.23] 0.21
BRAFmut V600E 38 25 23.7 [19.0–52.5] 1.70 [1.11–2.60] 0.01
BRA mut other 6 6 41.0 [29.1–NR] 1.31 [0.46–1.34] 0.38
Multivariable model
Variable; n = 582, number of events = 371
Multivariable HR
[CI 95%] P value (log-rank)
Male (vs. female) 1.16 [0.93–1.45] 0.18
Number of metastatic sites (2+ vs. 1) 1.29 [1.04–1.62] 0.02
Rectum (vs. left) 1.13 [0.87–1.46] 0.34
Right colon (vs. left) 1.28 [1.01–1.64] 0.05
Surgical resection of metastasis (vs. no) 0.35 [0.28–0.45] < 0.001
BRAF V600E mutation (vs. wt) 1.56 [0.98–2.49] 0.06
RAS mutation (vs. wt) 1.42 [1.15–1.77] 0.001
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BRAFV600E events according to tumor type, and we
also identified a more clonal distribution in breast can-
cer and melanoma, respectively, as compared with
CRC. On the other hand, our results suggest distinc-
tive genomic structures according to BRAF codon
affected, with non-V600-mutated tumors harboring a
clear clonal pattern. Importantly, none of the studies
reported above, including ours, have analyzed MAFs
in light of microsatellite instability (MSI), which is
associated with hypermutation rates and low copy
number alterations (The Cancer Genome Atlas, 2012).
Previous studies have found that the presence of a
low fraction of KRAS-mutated cells within primary
tumors may provide a reservoir for acquired resistance
to EGFR antibodies (Azuara et al., 2016; Laurent-Puig
et al., 2015). It is surprising that the measurement of
MAFs in primary samples correlates with the effects of
therapy in the metastatic setting, which suggests that in
addition to concordance of mutation events in primary
and metastatic samples, the relapsed lesions most likely
retain a similar genomic structure, with the same distri-
bution of MAFs. However, we found high KRAS
adjMAFs in metastatic sites of patients with a previous
diagnosis of KRAS wild-type CRC and exposed to
anti-EGFR therapy, suggesting clonal selection of
KRAS-mutant cells. Furthermore, differences in MAFs
of primary and unmatched metastatic sites for
BRAFV600E and TP53 mutations potentially reflect clo-
nal selection and/or acquired copy number events after
therapy. Indeed, the heterogeneity in copy number alter-
ations between matched primary tumors and different
metastatic lesions may explain some of the differences in
adjMAFs across sites (Sveen et al., 2016).
With regard to the clinical implications of driver
gene mutations, we observed that RAS and
BRAFV600E mutations, irrespective of adjMAFs, have
a negative effect on survival in the metastatic setting.
These results indicate that even if subclonal, a driver
Table 3. Matched targeted agent population.
Anti-MEK (n = 34) Anti-BRAF (n = 20) Anti-PI3K (n = 35)
Gene KRAS mutated BRAF mutated PIK3CA mutated
Variant G12 = 24 (71%) V600E = 20 (100%) Helical = 28 (80%)
G13 = 6 (17%) Kinase = 6 (17%)
Other = 4 (12%) Other = 1 (3%)
Coexisting mutation PIK3CA mutation = 12 (35%) PIK3CA mutation = 4 (20%) KRAS mutation = 13 (63%)
adjMAF (median, IQR) 0.55 (0.43–0.64) 0.25 (0.20–0.37) 0.34 (0.25–0.54)
Profiling
Sequenom 31 (91%) 12 (60%) 27 (77%)
MiSeq 3 (9%) 8 (40%) 8 (23%)
CRC primary 28 (82%) 19 (95%) 27 (77%)
Metastasis 6 (18%) 1 (5%) 8 (23%)
Regimen
Single-agent inhibitor 0 5 (25%) 35 (100%)
Doublet inhibitor 34 (100%) 7 (35%) 0
MEK + PI3K = 22 (65%) BRAF + MEK = 4 (20%)
MEK + IGFR1 = 8 (23%) BRAF + EGFR = 5 (25%)
MEK + HER = 4 (12%)
Triplet inhibitor 0 8 (40%) 0
BRAF + EGFR + PI3K = 4 (20%)
BRAF + EGFR + WNT = 2 (10%)
BRAF + EGFR + CDK = 1 (5%)
BRAF + EGFR + MEK = 1 (5%)
Response
Complete 0 1 (5%) 0
Partial 0 4 (20%) 0
Stable disease 7 (44%) 9 (45%) 11 (31%)
Progressive 19 (56%) 6 (30%) 22 (63%)
NA 0 0 2 (6%)
Discontinuation
Ongoing 0 1 (5%) 1 (3%)
Progression 31 (91%) 19 (95%) 30 (87%)
Toxicity 3 (9%) 0 2 (5%)
Other 0 0 2 (5%)
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event is biologically relevant. We acknowledge the fact
that MSI, a poor prognostic factor in metastatic CRC,
has not been taken into consideration in prognostic
models (Kim et al., 2016). Additionally, we found that
the clonality of KRAS, BRAFV600E, and PIK3CA
mutations did not predict benefit with matched tar-
geted agents. The negative findings, different from
other reports in EGFR-mutated lung cancer with
EGFR tyrosine kinase inhibitors (Ono et al., 2014;
Zhou et al., 2011), may be explained by the limited
benefit with the targeted therapies explored in our
cohort of chemotherapy-refractory CRC, particularly
with MEK and PI3K inhibitors in the KRAS- and
PIK3CA-mutant populations, respectively – the latter
harboring coexisting KRAS mutations known to con-
fer primary resistance to PI3K inhibitors as single
agents (Dienstmann et al., 2012). For patients treated
with BRAF inhibitors, while the poor response to tar-
geted therapy can be explained by constitutive activa-
tion of alternative signaling pathways (Prahallad et al.,
2012), the lack of correlation between BRAFV600E
adjMAFs measured in CRC primary tissues and TTP
in the metastatic setting may be related to a potential
shift in clonality status of BRAFV600E events from pri-
maries to metastases. The association between MAFs
of driver gene events identified through circulating
tumor DNA (ctDNA) NGS and clinical outcome
under targeted therapy should be investigated.
5. Conclusion
To conclude, our results suggest that driver gene muta-
tions can be subclonal and even ‘low MAF’ events in
NGS tests should be reported. As of today, the abso-
lute MAFs numbers cannot be used to optimize pre-
diction of prognosis or response to matched targeted
therapy in CRC. Major limitations of our study
include the relatively small and targeted gene panel
investigated, lack of copy number data to more pre-
cisely define clonality, and the absence of MSI status
annotation. From a research perspective, more work
needs to be conducted to increase biology understand-
ing before clinical translation. Finally, we believe that
analysis of paired primary and metastatic samples
from the same patient (longitudinal sampling), with
detailed treatment annotation, is crucial to further
assess clonality and subclonality patterns of genomic
events in cancer. Our work represents a foundation for
future efforts assessing the clinical significance of a
tumor’s genomic structure to guide precision cancer
therapy, opening the door for additional investigations
on the dynamics of clonal evolution after chemothera-
pies and targeted drugs.
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